Product Candidates

We are developing ANA598, a small-molecule, non-nucleoside inhibitor of the HCV polymerase (NS5B) for the treatment of chronic hepatitis C virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer. Both ANA598 and ANA773 are wholly owned by Anadys.